M.D. Ph.D. David D. Chang - President and CEO, Director at Allogene Therapeutics, Inc.

Insider Transactions and Holdings

Entity Type
Individual
Role
President and CEO, Director
Issuer Symbol
ALLO on Nasdaq
All Insider Reports
All Insider Reports

M.D. Ph.D. David D. Chang - trading volume in the past year for Allogene Therapeutics, Inc.

Holdings reported by M.D. Ph.D. David D. Chang for Allogene Therapeutics, Inc.

Security Num Shares Value Price $ Transaction Date Ownership Underlying Class Underlying Amount
Stock Option (Right to buy) 1,387,931 $10,808,407 $9.62 02 Feb 2026 Direct Common Stock
Common Stock 5,185,862 $9,334,551 $1.80 02 Feb 2026 Direct
Common Stock 1,201,108 $1,645,517 $1.37 02 Feb 2026 Indirect
Restricted Stock Unit 392,586 02 Feb 2026 Direct Common Stock

Transactions reported by M.D. Ph.D. David D. Chang for Allogene Therapeutics, Inc.

Sym Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.